Follow The Filings

NGNE Neurogene Inc.

Health Care, filed as NEUROGENE INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.5%
  • $2.8M
  • 1 add

In 2026 Q2 Nathan Fischel added to Neurogene.

Who owns this now

Largest portfolio weights among holders, up to 0.5% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Add 0.53%

Who owns NGNE

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.53%, was 0.26% Add +57.2% 89,032 $2.8M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by NGNE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NGNE insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $902K sold by 2 insiders under 10b5-1 plans
  1. Christine Mikail Cvijic CFO
    Planned sale
    $173K 4,800 shares at $36.12 5.4% of stake
    Traded Jul 6–7 Filed Jul 7
    ↗
  2. Christine Mikail Cvijic CFO
    Planned sale
    $167K 4,800 shares at $34.71 5.1% of stake
    Traded Jul 1–2 Filed Jul 2
    ↗
  3. Christine Mikail Cvijic CFO
    Planned sale
    $300K 9,600 shares at $31.25 9.3% of stake
    Traded May 6 Filed May 8
    ↗
  4. Stuart Cobb Chief Scientific Officer
    Planned sale
    $141K 6,797 shares at $20.81 18% of stake
    Traded Mar 13 Filed Mar 17
    ↗
  5. Christine Mikail Cvijic CFO
    Planned sale
    $121K 4,800 shares at $25.11 4.2% of stake
    Traded Feb 27 Filed Mar 3
    ↗

Also filed in the last 12 months, not counted as buying or selling: 6 sales to cover taxes, 4 stock grants, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $925,000 $0.00
Net income -$36.32M -$75.14M -$90.35M
Net margin * — -8123.7% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $200.35M $315.92M $271.77M
Total non-current assets * $22.22M $19.81M $16.83M
Total assets $222.57M $335.73M $288.6M
Total current liabilities $22.97M $15.16M $16.41M
Total non-current liabilities * $13.58M $10.2M $7.31M
Total equity $186.02M $310.38M $264.89M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$51.42M -$70.6M -$77.17M
Cash from investing $25.64M -$125.26M $14M
Cash from financing $92.48M $184.07M $30.43M
Net change in cash $66.7M -$11.79M -$32.74M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.